hotspot -WSS

hotspot

author：Wikipedia 2025-09-27 16:46:08 - browse：23364

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Wildfire smoke exposes gaps in outdoor worker protections

hotspot

focus

WSS

Flu vaccine offering decent levels of protection this winter, new data show

ChatGPT in medicine: STAT answers readers' burning questions

Walensky prepares to leave CDC — and Congress — behind

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Duchenne breakthrough therapy leaves behind pioneering families

International team creates first chimeric human

hotspot

hotspot

hotspot

How one medical school became remarkably diverse

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Hollywood unions extend contract negotiations for actors

Why getting cancer drugs just got harder for rural patients

Wildfire smoke exposes gaps in outdoor worker protections

Affirmative action in medical school literally saved lives

Supreme Court strikes down use of affirmative action

An inside look at PIPEs, biotech's buzzy new financing tool

Moonlake's readout produced a cash windfall. Risks remain

The cancer drug shortage isn’t new — and neither are the solutions

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Jerome Adams on the need for new antivirals for Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

In search for therapies for solid tumors, companies turn to claudin

Change Healthcare cyberattack outage could last weeks

In search for therapies for solid tumors, companies turn to claudin

focus

hotspot

focus

knowledge